Conditions: Chronic Hepatitis C Hepatitis C Virus
Keywords: Hepatitis C HCV Interferon Free Chronic Hepatitis C Hepatitis C virus Hepatitis C Genotype 3
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 10
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the safety and antiviral effect of ABT-450/r and ABT-530 coadministered with and without Ribavirin in adults with genotype 3 HCV infection.

Detailed description:
Once the efficacy and safety data were obtained from participants administered ABT-450/r + ABT-530 + RBV weight-based (Arm 1) in Study M14-213, the decision was made to end this study before subjects were enrolled into Arm 2.

Arms:
arm 1: ABT-450/r (150 mg/100 mg) once daily (QD) co-administered with ABT-530 (120 mg) once daily (QD) plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks.

Interventions: intervention 1: ABT-450/ritonavir (r) intervention 2: ABT-530 intervention 3: Ribavirin (RBV)
Intervention descriptions: intervention 1: Tablet intervention 2: Tablet intervention 3: Tablet

Protocol document: